QBW276 / Novartis - LARVOL DELTA

ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo. (PubMed, J Cyst Fibros) - "These data support that the ENaC blocker hypothesis is yet to be appropriately tested in pwCF. ETD001 has a profile that enables dosing at a level sufficient to provide a long duration of action in a Phase 2 clinical study in pwCF scheduled for 2024."

Journal • Preclinical • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis (clinicaltrials.gov) - P1/2; N=16; Completed; Sponsor: Novartis Pharmaceuticals; Recruiting ➔ Completed; N=56 ➔ 16

Clinical • Enrollment change • Trial completion